On December 31, 2025, Rani Therapeutics Holdings, Inc. terminated a Tax Receivable Agreement and modified its governance structure, including reducing Class B common stock voting rights from 10 votes to 1 vote. This event is significant from an equity investor perspective and carries a neutral sentiment, as it mainly deals with internal governance adjustments.